Biomea Fusion, Inc. (NasdaqGS: BMEA)
Health Care · Biotechnology · US
$1.32
+5.60% today · -28.5% 1Y
Biomea Fusion, Inc. (NasdaqGS: BMEA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $95.68M and employs 37 people.
Over the last twelve months the share price has lost 28.5%, trading between 0.87 and 2.99.
Tweenvest scores Biomea Fusion, Inc. across four factors: quality 44/100, value 78/100. Its strongest factor is value.
BMEA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $95.68M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.47
- Dividend yield
- —
- Beta (5Y)
- -0.30
- 52-week high
- $2.99
- 52-week low
- $0.87
- Avg volume (3M)
- —
- Shares outstanding
- 72.48M
- Employees
- 37
- Next earnings
- —
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
- ISIN
- US09077A1060
- Founded
- 2017
- Listed since
- Apr 16, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Novogenia AGMUN: 7V0 | $98.11M | €7.20 | — |
| Y-Biologics, Inc.KOSDAQ: A338840 | $97.21M | ₩8,520.00 | +2.16% |
| Senhwa Biosciences, Inc.TPEX: 6492 | $96.53M | NT$34.40 | +0.58% |
| Medivir AB (publ)OM: MVIR | $96.31M | Skr1.55 | -2.15% |
| Atara Biotherapeutics, Inc.NasdaqGS: ATRA | $94.05M | $9.37 | -3.90% |
| Dimerix LimitedASX: DXB | $93.89M | AU$0.23 | -8.16% |
| Genexine, Inc.KOSDAQ: A095700 | $93.54M | ₩2,770.00 | +1.28% |
| Devyser Diagnostics AB (publ)OM: DVYSR | $92.23M | Skr52.60 | -4.01% |
Figures last refreshed Oct 4, 2026.